Journal Article

Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes

Diaz-Manera, Jordi, de Luna, Noemí, Suarez-Calvet, Xavier, Illa, Isabel, Gallardo, Eduard, Fernández-Simón, Esther, Lleixà, Cinta

2020

Overview

Background Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is implicated in vesicle fusion, trafficking, and membrane repair. Muscle biopsy of patients with dysferlinopathy is characterized by the presence of inflammatory infiltrates. Studies in the muscle of both human and mouse models of dysferlinopathy suggest dysferlin deficient muscle plays a role in this inflammation by releasing thrombospondin-1. It has also been reported that vitamin D3 treatment enhances dysferlin expression. The ubiquitin-proteasome system recognizes and removes proteins that fail to fold or assemble properly and previous studies suggest that its inhibition could have a therapeutic effect in muscle dystrophies. Here we assessed whether inhibition of the ubiquitin proteasome system prevented degradation of dysferlin in immortalized myoblasts from a patients with two missense mutations in exon 44. Methods To assess proteasome inhibition we treated dysferlin deficient myotubes with EB1089, a vitamin D3 analog, oprozomib and ixazomib. Western blot was performed to analyze the effect of these treatments on the recovery of dysferlin and myogenin expression. TSP-1 was quantified using the enzyme-linked immunosorbent assay to analyze the effect of these drugs on its release. A membrane repair assay was designed to assess the ability of treated myotubes to recover after membrane injury and fusion index was also measured with the different treatments. Data were analyzed using a one-way ANOVA test followed by Tukey post hoc test and analysis of variance. A p  ≤ 0.05 was considered statistically significant. Results Treatment with proteasome inhibitors and EB1089 resulted in a trend towards an increase in dysferlin and myogenin expression. Furthermore, EB1089 and proteasome inhibitors reduced the release of TSP-1 in myotubes. However, no effect was observed on the repair of muscle membrane after injury. Conclusions Our findings indicate that the ubiquitin-proteasome system might not be the main mechanism of mutant dysferlin degradation. However, its inhibition could help to improve muscle inflammation by reducing TSP-1 release.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Animal models / Antibodies / Binding sites / Biopsy / Drug delivery / Drug therapy / Dysferlin / Dysferlin - genetics / Enzyme-linked immunosorbent assay / Epidemiology / Gene expression / Health aspects / Humans / Inflammation / Internal Medicine / Medicine / Medicine & Public Health / Membrane fusion / Membrane proteins / Membrane trafficking / Membranes / Missense mutation / Muscle Fibers, Skeletal / Muscle proteins / Muscle Proteins - genetics / Muscle, Skeletal / Muscular dystrophy / Musculoskeletal diseases / Musculoskeletal system / Mutation / Myoblasts / Myogenin / Myotubes / Neuromuscular diseases / Orthopedics / Pathophysiology of musculoskeletal disorders / Patient outcomes / Patients / Proteasome / Proteasome inhibitors / Proteasome Inhibitors - pharmacology / Proteasomes / Proteins / Rehabilitation / Research Article / Rheumatology / Sarcolemma / Sports Medicine / Statistical analysis / Thrombospondin / Thrombospondin 1 / Ubiquitin / Vesicle fusion / Vitamin D3